Y-mAbs Therapeutics NASDAQ:YMAB Stock Rating Lowered by Morgan Stanley

This company is expected to post quarterly loss of $1.34 per share in its upcoming report, which represents a year-over-year change of -78.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Are you looking for nvax hashtags to boost likes and followers on your Instagram post? If Yes, then you have reached at right place because this page has a collection of latest nvax hashtags for Instagram, Twitter, Facebook, Tumblr, Youtube, TikTok which are updated in 2023.

Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY. When you’re researching the best stocks to buy and watch, keep a close on eye on relative price strength.

Tags for likes such as L4L are very popular, with over 80 million tagged photos. Tags for follows such as F4F are also popular, with over 70 million tagged photos. Instagram hashtags can be used to get more likes or followers by making it easier for people to find your photos.

BNP Paribas Arbitrage SA lifted its holdings in shares of Y-mAbs Therapeutics by 172.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock valued at $121,000 after buying an additional 5,052 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at approximately $156,000.

YmAbs Therapeutics, Inc., which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $12.54 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 7.29%. The company has topped consensus revenue estimates just once over the last four quarters. A quarter ago, it was expected that this company would post a loss of $0.68 per share when it actually produced a loss of $0.94, delivering a surprise of -38.24%. For YmAbs Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions.

The Company has incurred annual losses since inception, and expects to continue to incur increasing net operating losses and significant expenses for the foreseeable future. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Get Started Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content. Earnings growth declined in the company’s most recent report from 0% to -185%, but the top line rose from -54% to 95%. On Friday, Y-mabs Therapeutics received an upgrade to its Relative Strength Rating, from 82 to 95. Upgrade to MarketBeat Daily Premium to get early delivery, personalized stock alerts, portfolio monitoring tools, and more.

Institutional investors and hedge funds own 53.96% of the company’s stock. Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. 2 Wall Street research analysts have issued twelve-month mac utility homebrew finally apple m1 target prices for iBio’s stock. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication.

So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here. Institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank purchased a new stake in Y-mAbs Therapeutics during the first quarter worth approximately $68,000.

Not only does this include current consensus earnings expectations for the coming quarter, but also how these expectations have changed lately. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better. Exact Sciences’ consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.09. Compared to the company’s year-ago EPS, this represents a change of -12.4%. Free Report) , another stock in the same industry, closed the last trading session 7.7% higher at $34.44.